Evelo Biosciences - EVLO Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month target prices for Evelo Biosciences' stock. Their EVLO share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's stock price to reach $3.17 in the next twelve months. This suggests a possible upside of 1,433.5% from the stock's current price.
View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts.

Evelo Biosciences' stock was trading at $1.61 at the beginning of 2023. Since then, EVLO shares have decreased by 87.2% and is now trading at $0.2065.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our EVLO earnings forecast.

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. During the same quarter in the previous year, the company posted ($0.45) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Evelo Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.56%), Mayo Clinic (0.44%), Mayo Clinic (0.44%), Susquehanna International Group LLP (0.14%), Trustees of Columbia University in the City of New York (0.11%) and Citigroup Inc. (0.09%). Insiders that own company stock include David R Epstein, Stephen J Carriere, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends.

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVLO stock can currently be purchased for approximately $0.21.

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $22.91 million. The company earns $-114,530,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

The company employs 122 workers across the globe.

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.